Outset Medical Launches Inaugural ESG Report
“At Outset, our ESG journey is rooted in our mission to catalyze permanent and profound change in where, when, and how dialysis is delivered to lower costs and restore identity, agency, and self-worth to patients,” said
Notable ESG achievements during Outset’s first year as a public company include:
Raising awareness of patient disparities in kidney care
Advocating for progressive, patient-centric policies to improve the lives of dialysis patients has been, and continues to be, a key area of focus for Outset, particularly as COVID-19’s disparate impact on people of color, and on people with end stage kidney disease, shined a light on the compounding effects of underlying racial health inequities. We are working with leading patient-focused organizations to promote increased access to home healthcare, drive better outcomes for all kidney patients, and help erase racial disparities in home dialysis use.
Championing gender diversity at the board level
Outset’s Board of Directors is comprised of more women than men. We believe this composition places us among a select group of companies that are leading the way in closing the gender gap in corporate boardrooms. We intend to push even further in setting a new standard for diversity, equity, inclusion, and belonging.
Focusing on environmental sustainability and company culture at Outset Medical Mexico (OMM)
We made environmental sustainability a key focus during the development of our OMM manufacturing facility, particularly as it pertains to water conservation and recycling, energy efficiency, and waste management. We set very ambitious water recycling goals and exceeded them in our first year of operation. We also established ambitious workplace goals by promoting an all-inclusive organization where respect, collaboration, and merit-based recognition are deeply embedded.
Outset’s 2021 ESG report has been developed to present information about Outset’s business and ESG practices in areas we believe to be most useful to investors and other stakeholders. The report addresses specific standards defined by the
To view Outset´s ESG report, please visit the ESG section of the Company’s investor relations website: http://investors.outsetmedical.com/environmental-social-and-governance
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding Outset’s current and future compliance and sustainability initiatives, anticipated environmental, social, and governance policies and practices, and other plans, prospects, goals, initiatives, strategies, or future actions, events, or performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause actual results and other events to differ materially from those expressed or implied in such statements. These risks and uncertainties include risks described in the Risk Factors section of Outset’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the